FDAnews
www.fdanews.com/articles/100641-seattle-genetics-reports-sgn-35-data

Seattle Genetics Reports SGN-35 Data

November 5, 2007

Seattle Genetics discussed data from the Phase I trial of SGN-35, a proprietary antibody-drug conjugate product candidate in patients with relapsed or refractory Hodgkin lymphoma and other CD30-positive malignancies.

More than 75 percent of patients treated in the study achieved tumor reductions across all dose levels evaluated, including four with partial responses. Twelve additional patients had stable disease and seven had progressive disease. Of the four patients with partial responses, three are continuing in the study, including one patient who has been receiving treatment for more than seven months, Seattle Genetics said.

SGN-35 has been generally well tolerated, and the maximum tolerated dose has not yet been defined.